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Carotid Atherosclerosis Progression in Familial
Hypercholesterolemia Patients
A Pooled Analysis of the ASAP, ENHANCE, RADIANCE 1, and
CAPTIVATE Studies
Menno Vergeer, MD; Rong Zhou, PhD; Michiel L. Bots, MD, PhD; Raphae¨l Duivenvoorden, MD;
Joerg Koglin, MD; Fatima Akdim, MD; Yale B. Mitchel, MD; Roeland Huijgen, MD;
Aditi Sapre, PhD; Eric de Groot, MD, PhD; Eric J.G. Sijbrands, MD, PhD; Richard C. Pasternak, MD;
Claude Gagne´, MD; A. David Marais, MD; Christie M. Ballantyne, MD; Jonathan L. Isaacsohn, MD;
Anton F. Stalenhoef, MD, PhD; John J.P. Kastelein, MD, PhD
Background—Until recently, patients with heterozygous familial hypercholesterolemia (HeFH) were considered the best
subjects for the assessment of changes in carotid intima-media thickness (cIMT) in randomized intervention trials. Our
aims were to investigate whether contemporary statin-treated HeFH patients still show accelerated cIMT increase and
to assess the impact of statin treatment, before and after random assignment, on atherosclerosis progression.
Methods and Results—We retrospectively evaluated cIMT change, and prior statin treatment and postbaseline LDL-C
change as predictors of cIMT change, in 1513 HeFH patients who were randomly assigned to the statin arms of the early
ASAP and more recent RADIANCE 1, CAPTIVATE, and ENHANCE studies. In the 3 recent studies combined, mean
cIMT increased at only 33% of the rate of the simvastatin-treated patients in the ASAP study (0.014 mm/2 years [95%
confidence interval, 0.0003–0.028] versus 0.041 mm/2 years [95% confidence interval, 0.020–0.061]; P0.05).
Patients whose statin therapy could be intensified, as evidenced by an LDL-C decrease after the initiation of on-trial
statin therapy, showed cIMT decrease in the first 6 to 12 months and a much lower cIMT increase measured over the
full 2 years. In line with this, previously statin-naive HeFH patients showed a lower overall cIMT increase.
Conclusions—Over the years, intensification of statin therapy in HeFH patients has resulted in an impressive decrease
in carotid atherosclerosis progression. In studies that assess other antiatherosclerotic modalities, statin therapy may
still induce rapid changes in cIMT. For future cIMT studies, our analyses suggest that patient populations other
than intensively pretreated HeFH patients should be selected and that the statin regimen should not be changed on
study initiation. (Circ Cardiovasc Imaging. 2010;3:398-404.)
Key Words: imaging  familial hypercholesterolemia
B-mode ultrasound carotid intima-media thickness (cIMT)is the most widely used and best validated imaging
modality for intervention studies that evaluate the effect of
any given treatment on the progression of atherosclerosis.1,2
Patients with heterozygous familial hypercholesterolemia
(HeFH) were often selected for these studies because of their
increased risk of premature coronary artery disease and
accelerated cIMT increase from childhood onward.3,4 Indeed,
one of the first cIMT trials in HeFH patients, the Atorvastatin
versus Simvastatin on Atherosclerosis Progression (ASAP)
study, demonstrated a clear benefit of aggressive lipid-
lowering with atorvastatin 80 mg versus conventional lipid-
lowering with simvastatin 40 mg, on the rate of arterial wall
thickening.5 However, the implementation of active (genetic)
screening programs for HeFH has led to earlier diagnosis and
thus earlier intervention in the natural course of this disease.6
Furthermore, the standard of clinical care for patients with
HeFH has changed substantially over the past decade: Life-
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style interventions, statin therapy, as well as the treatment of
other cardiovascular risk factors have all considerably inten-
sified. In fact, in a recent study, the introduction of statin
therapy in HeFH patients was demonstrated to have resulted
in an 80% reduction of cardiovascular risk.7
Clinical Perspective on p 404
This finding may bear relevance to cIMT trials in contem-
porary HeFH patients because those studies mostly include
patients who have been pretreated with statins and routinely
use intensive statin therapy in both treatment arms. This
raises several questions. First, do HeFH patients still exhibit
sufficient atherosclerosis progression for inclusion in cIMT
intervention studies? Second, has the intensification of statin
treatment in the contemporary HeFH population affected
their cIMT readings? More specifically, does intensification
of the statin regimen at the beginning of a trial reduce
subsequent cIMT change, and, related to this question, does
pretreatment with statin therapy result in a different rate of
cIMT change? To address these questions, we performed post
hoc analyses in the statin arms of 4 randomized controlled
cIMT trials that included HeFH patients, namely ASAP,
Rating Atherosclerotic Disease Change by Imaging With A
New CETP Inhibitor 1 (RADIANCE 1),8 Ezetimibe and
Simvastatin in Hypercholesterolemia Enhances Atherosclero-
sis Regression (ENHANCE),9 and Efficacy and Safety of the
ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Pro-
gression of Carotid Artery Disease (CAPTIVATE).10
Methods
Data Sources
Individual patient data from the statin arms of the ASAP, RADI-
ANCE 1, CAPTIVATE, and ENHANCE studies were merged.
Design and results of these studies were published previously.
Briefly, ASAP enrolled HeFH patients who were previously un-
treated or treated for up to 1 year or who had low-density lipoprotein
cholesterol (LDL-C) levels above 173 mg/dL. Patients were then
randomized to receive treatment with either atorvastatin 80 mg or
simvastatin 40 mg. The primary end point was the change in mean
cIMT over 2 years. Both treatment arms were included in the present
analyses. RADIANCE 1 enrolled HeFH patients, and titrated with
atorvastatin to target low-density lipoprotein cholesterol (LDL-C)
levels according to NCEP ATP-III criteria or to a maximally
tolerated dose.11 Patients were then randomly assigned to receive
torcetrapib or placebo on top of this atorvastatin regimen. The
primary end point was the annualized rate of change in the maximum
cIMT of 12 predefined carotid segments. Data from the atorvastatin
monotherapy arm were included in the present analysis. CAPTI-
VATE enrolled HeFH patients who were randomly assigned to
receive pactimibe or placebo on top of standard lipid-lowering
therapy. The primary end point of this study was the change in mean
cIMT over 2 years. The study was prematurely terminated after the
development of pactimibe was halted. Data from the standard
lipid-lowering therapy arm were included in our analysis. CAPTI-
VATE differs from the other studies in the fact that besides the
addition of pactimibe or placebo, lipid-lowering therapy was not
changed at the start of the trial. ENHANCE included HeFH patients
who were randomly assigned to receive simvastatin 80 mg and
ezetimibe 10 mg or simvastatin 80 mg monotherapy. The primary
end point was 2-year change in mean cIMT, which was defined as
the average of the means of the far-wall intima-media thickness of
the right and left common carotid arteries, carotid bulbs, and internal
carotid arteries. Only the monotherapy arm was included in the
present analysis.
Extraction of Data
We extracted segment level cIMT data and calculated mean cIMT
for each patient at each available time point for all segments, using
measures of the far walls of the left and right common carotid artery,
left and right internal carotid artery and the left and right carotid
bulb. We specifically did not strive to replicate the originally
published cIMT results but instead chose to construct a measure of
cIMT, homogeneous across all studies. We extracted baseline data
on prior statin use and on the variables age, sex, body mass index
(BMI), presence/absence of coronary artery disease (CAD), diabetes
mellitus, (treated) hypertension, total cholesterol, LDL-C, high-
density lipoprotein cholesterol (HDL-C), and triglycerides. We also
extracted data on LDL-C at end-of-study.
End Points
End points of our analysis were 1-year and 2-year change of mean
cIMT of all segments and 1-year and 2-year change of the mean
intima-media thickness of both common carotid arteries, which will
be referred to as CCA-IMT. The latter measure has been used as a
primary end point in a number of recent trials.12–17
Data Analyses
Analyses were performed in subjects with complete data, or, alter-
natively, missing data for cIMT (112 subjects, 7%) were imputed
using multiple imputation according to the Markov chain Monte
Carlo method. First, to assess differences in carotid atherosclerosis
progression between contemporary patients and the early HeFH
population, mean cIMT changes in the control arms of the EN-
HANCE, CAPTIVATE, and RADIANCE 1 trial were compared
with mean cIMT change in the ASAP simvastatin arm. The analysis
included a fixed effect for each of the studies and inferred on the
average difference between the three contemporary studies and
ASAP.
Second, we assessed whether intensification of statin therapy at
the start of the trial affects on subsequent cIMT change. We could
evaluate this in all studies that incorporated a switch in statin therapy
at their initiation (ASAP, ENHANCE, and RADIANCE 1). Because
the impact of a new statin regimen on LDL-C can be expected to
differ between patients, and because a quantitative comparison of the
potency of different statins in different dosages is impossible, we
decided to select the change in LDL-C as a proxy for the change in
intensity of statin therapy. We divided patients into 2 groups: those
who showed a decrease of LDL-C levels after initiation of on-trial
statin therapy (end-of-study LDL-C screening visit LDL-C)
versus those who showed no decrease of LDL-C after the start of
study (end-of-study LDL-C screening visit LDL-C). The first
group (“LDL decrease”) was assumed to have received more
intensive statin therapy during the trial than before the trial; the
second group (“no LDL decrease”) was assumed to have received
less or equally intensive statin therapy during the trial compared
with before the trial.
Third, to assess the potential of prior statin use as an independent
predictor for all cIMT change end points, a 2-level random-effects
regression analysis was conducted adjusting for all baseline variables
mentioned under the heading “extraction of data,” incorporating
study as a random effect. The likelihood ratio test was used to
compare deviance statistics for nested models, with the significance
level set at a probability value of 0.10. We chose not to adjust for
baseline cIMT because this might have resulted in a considerable
bias related to measurement error, as described elsewhere.18–20
Results are presented as mean change in cIMT with corresponding
standard error and probability value. Analyses were performed using
SAS, version 9.2.
Results
We extracted data from four different cIMT trials that
enrolled HeFH patients. More than 70% of patients in the
more recent trials had received intensive lipid-lowering ther-
apy before enrollment as compared with 41% in the earlier
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ASAP study. In all contemporary studies, statin therapy
during the trial was more intensive than in the ASAP
simvastatin arm. Differences in statin treatment before and
during the trial for each contemporary study, compared with
the ASAP study, are shown in Table 1.
Table 2 shows the baseline characteristics of all 1513
subjects. We compared mean cIMT change in contemporary
studies with mean cIMT change in the ASAP simvastatin
arm. After 2 years, cIMT increase in recent studies was 33%
of that in the earlier ASAP study (0.014 mm [95% confidence
interval (CI), 0.0003–0.028] versus 0.041 mm [95% CI,
0.020–0.061], P0.05). Interestingly, in both ASAP and the
newer studies, cIMT increased faster in the second year than
in the first year (Figure 1).
Next, we assessed whether intensification of statin therapy
at the start of the trial reduces subsequent cIMT change. To
Table 1. Statin Therapy Before and During cIMT Progression Trials in HeFH Patients
n
Year of
Publication
Pretreatment, n (%)
Control Arm TherapyAny Statin Intensive Therapy
Early
ASAP 325 2001 221 (68) 134 (41) Simvastatin 40 mg
Contemporary
RADIANCE 1 454 2007 390 (86) 331 (73) Atorvastatin mean 57 mg
CAPTIVATE 371 2008 357 (96) 299 (81) Same as pretreatment
ENHANCE 363 2008 295 (81) 257 (71) Simvastatin 80 mg
Six to 7 years after ASAP, both pretreatment and on-trial treatment with lipid-lowering therapy had intensified
considerably.
Intensive therapy was defined as simvastatin 40 mg or atorvastatin 20 mg, or any statin in combination
with other lipid-lowering therapy.
Table 2. Baseline Characteristics of the Studied Populations at Screening
ASAP
(n325)
RADIANCE 1
(n454)
CAPTIVATE
(n371)
ENHANCE
(n363)
All Studies
(n1513)
Age, y 4911 4513 549 4610 4811
Sex, n (%)
Female 197 (60.6) 222 (48.9) 145 (39.1) 184 (50.7) 748 (49.4)
History of CAD, n (%)
Presence 48 (14.8) 99 (21.8) 116 (31.3) 9 (2.5) 272 (18.0)
Absence 277 (85.2) 355 (78.2) 255 (68.7) 354 (97.5) 1241 (82.0)
Diabetes mellitus, n (%)
Presence 7 (2.2) 19 (4.2) 22 (5.9) 5 (1.4) 53 (3.5)
Absence 318 (97.8) 435 (95.8) 349 (94.1) 358 (98.6) 1460 (96.5)
Hypertension, n (%)
Presence 32 (9.8) 114 (25.1) 104 (28.0) 52 (14.3) 302 (20.0)
Absence 293 (90.2) 340 (74.9) 267 (72.0) 311 (85.7) 1211 (80.0)
BMI 30 kg/m2
Yes 34 (10.5) 107 (23.6) 94 (25.3) 83 (22.9) 318 (21.0)
No 291 (89.5) 346 (76.2) 275 (74.1) 278 (76.6) 1190 (78.7)
Unknown 0 (0.0) 1 (0.2) 2 (0.5) 2 (0.6) 5 (0.3)
Current smoker
Yes 101 (31.1) 95 (20.9) 51 (13.7) 104 (28.7) 351 (23.2)
No 224 (68.9) 359 (79.1) 320 (86.3) 259 (71.3) 1162 (76.8)
Cholesterol, mg/dL
LDL 22356 16760 14336 22564 18766
HDL 4813 5313 5314 5116 5114
Triglycerides, mg/dL, median
(interquartile range)
112 (80–162) 102 (80–142) 118 (90–161) 121 (89–162) 113 (83–158)
Mean cIMT, mm 0.9360.222 0.9500.284 0.8070.172 0.6980.142 0.8560.244
CCA-IMT, mm 0.8740.208 0.8210.216 0.7700.175 0.6810.163 0.7880.207
Values are meansSD unless otherwise indicated.
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this end, we evaluated whether patients who had a postbase-
line decrease in LDL-C showed a different cIMT change
from patients who did not. In CAPTIVATE there was no
meaningful difference between on-trial LDL-C and baseline
LDL-C because patients were continued on their own statin
therapy. However, in the studies that switched to a different
statin regimen at baseline—ASAP, RADIANCE 1, and
ENHANCE—those patients with a decrease of plasma
LDL-C after study initiation showed less carotid atheroscle-
rosis progression than patients whose LDL-C did not de-
crease (Figure 2). Furthermore, patients with a decrease in
LDL-C showed a rapid regression of carotid atherosclerosis
during the first 6 to 12 months compared with baseline
(0.012 mm [95% CI, 0.018–0.005] at 6 months and
0.013 mm [95% CI, 0.020–0.005] at 12 months in the
combined analysis; both different from zero with P0.0005
and P0.001, respectively). These data suggest that intensi-
fication of statin therapy at the start of the study retards the
progression of carotid atherosclerosis.
We hypothesized that such an effect would mainly occur in
statin-naive patients. To test this hypothesis, we assessed the
association between prior statin use and subsequent cIMT
change, as defined by different criteria (1-year mean cIMT
change, 2-year mean cIMT change, 1-year CCA-IMT change,
and 2-year mean CCA-IMT change), adjusting for age, sex,
BMI 30 kg/m2, history of CAD, history of diabetes, history
of hypertension, and LDL-C, HDL-C, and triglycerides at
screening. All variables were entered into the models, and
only those with a P0.10 were retained. Final models are
depicted in Table 3. Prior statin use was positively associated
with cIMT change (ie, previously statin-naive patients, whose
statin therapy was first initiated as part of the trial, had a
lower subsequent cIMT increase). In line with this, baseline
triglycerides were negatively associated with cIMT change.
Age and smoking were positively associated with cIMT
change. In exploratory analyses we found that imputation of
missing cIMT data did not materially change the results.
Furthermore, the direction of association between prior statin
use and cIMT change was consistent in ASAP, RADIANCE
1, and ENHANCE, ruling out confounding by study (Supple-
mental Table). However, the association was approximately
6-fold weaker in CAPTIVATE than in the other studies
(parameter estimate for association with 2-year change in
mean cIMT, 0.0034 mm [standard error, 0.1271], P0.98),
suggesting that prior statin use is only an important predictor
of cIMT change if the statin regime is changed at the start of
the study.
Discussion
In the current analysis, we demonstrate that the rate of cIMT
change in intensively treated contemporary HeFH patients is
a third of that in the less intensively treated HeFH population
of the early ASAP trial. Also within studies, a reduction of
carotid atherosclerosis progression occurred in patients
whose statin therapy was intensified. In fact, these patients
even showed regression of atherosclerosis in the first 6 to 12
months, also while they were randomly assigned to the
control arm of these studies. In contrast, patients who did not
exhibit an LDL-C reduction on trial medication did not show
regression of carotid atherosclerosis and had a higher overall
cIMT increase. In line with this, previously statin-naive
HeFH patients, who received statin therapy for the first time
during the trial, showed a lower overall cIMT increase,
indicating that these patients have a particularly strong
statin-induced suppression of cIMT increase. These data
demonstrate that the intensification of statin therapy that
Figure 1. Mean cIMT change in the statin monotherapy arms of
contemporary studies (striped line) versus the ASAP simvastatin
arm (solid line). In both instances, cIMT increase is more pro-
nounced in the second year than in the first year. In the newer
studies (RADIANCE 1, ENHANCE, and CAPTIVATE), cIMT
change is more than 3 times lower after 2 years. Error bars rep-
resent standard errors. *P0.05.
Figure 2. Mean cIMT change in patients according to change in
LDL. In ASAP, ENHANCE, and RADIANCE 1, cIMT progression
was lower in patients with an LDL decrease (striped line;
n235, n218, and n260, respectively) after initiation of
on-trial intensive statin therapy than in patients without an LDL
decrease (solid line; n41, n95, and n127, respectively). In
all studies, cIMT tended to rapidly regress in the first 6 to 12
months in case of an LDL decrease. Error bars represent stan-
dard errors. Probability values are for the difference between
groups. *P0.05, **P0.01, ***P0.001.
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HeFH patients have witnessed over the past decade has
substantially slowed down atherosclerosis progression. Fur-
thermore, they suggest that at least part of the effect of statin
therapy on carotid atherosclerosis is rapidly achieved.
Statins Retard Progression of
Carotid Atherosclerosis
After the publication of the ENHANCE study, which showed
no benefit of adding ezetimibe to simvastatin 80 mg on cIMT
change despite a substantial additional LDL-C reduction,9 its
failure has been subject of intense debate.21,22 Proposed
explanations broadly fell into 3 categories: First, the mea-
surement of cIMT change may not have accurately reflected
changes in atherosclerotic burden; second, the compound
ezetimibe may lack vascular benefit; and third, cIMT change
may have been too low in contemporary HeFH patients to
detect a difference between control and intervention arm.9
In the current study, we found evidence to support the last
explanation: cIMT change in contemporary HeFH patients is
considerably lower than in patients who used simvastatin 40
mg in ASAP. Further analyses confirmed that statin treatment
remains an important determinant of cIMT change in HeFH
patients: Patients who received more intensive statin therapy
during the study than before the study exhibited a reduced
cIMT increase compared with other patients. Thus, as may
have been expected, statin intensification suppresses carotid
atherosclerosis progression. In line with this, this effect is
mainly observed in previously statin-naive patients, whom we
found to display the lowest cIMT increase during the trials.
Rapid Effect of Statins
In addition, we found that intensification of statin therapy is
associated with regression of carotid atherosclerosis in the
first 6 to 12 months, suggesting rapid statin-induced carotid
wall changes. This finding is supported by other recent
studies that showed that the initiation of statin therapy leads
to a rapid delipidation of carotid plaque: After treating
patients with pravastatin for 12 weeks, atherosclerotic
plaques removed from their carotid arteries through endarter-
ectomy showed a significantly diminished lipid content, as
well as decreased lipid oxidation and inflammation parame-
ters.23 Rapid statin-induced plaque delipidation has not only
been demonstrated by histology but also by MRI. A mere 6
months after the initiation of simvastatin therapy, plaque
volume reduction was observed in the thoracic aorta.24
Indeed, in the ASAP trial as well as in the ASAP extension
study, carotid atherosclerosis regression was most prominent
during the first year of therapy with atorvastatin 80 mg,
supporting the notion that delipidation of the vessel wall may
be attained quite rapidly.5,25 In line with this, findings from
the recent METEOR study show an effect on cIMT change
after 12 months of rosuvastatin therapy.26
Similar results have been observed after a single infusion
of reconstituted high-density lipoprotein: Lipid content, mac-
rophage size, and measures of inflammation in plaques from
femoral arteries were reduced.27 Our data show that rapid
statin-induced vessel wall delipidation also plays a role in
trials that were in fact not designed to assess the effects of
statins.
Clinical Implications
After the ASAP study, which showed a large difference in
cIMT change between HeFH patients treated with simvastatin
40 mg and HeFH patients treated with atorvastatin 80 mg,5
these individuals were considered an ideal population to
assess novel therapeutic strategies. However, as more potent
lipid-lowering therapies became available in recent years,
treatment of HeFH patients has improved and cIMT charac-
teristics of this population have changed significantly. The
results of the present study imply that contemporary HeFH
patients exhibit only a very modest progression of arterial
wall thickening because of intensive statin therapy before as
well as during trials. This indicates that the current HeFH
patient population is less suited for inclusion in cIMT trials
that evaluate novel therapeutic strategies on top of (intensive)
statin therapy and suggests that other patient populations
should be considered for such trials. In this respect, patients
with mixed dyslipidemia may be a better choice. RADIANCE
2 assessed the effects of torcetrapib/atorvastatin on cIMT
change in this patient population.28 Two-year mean cIMT
change in patients who received atorvastatin monotherapy
was 0.0461 mm (standard error, 0.009), which is comparable
to that of the HeFH patients in the ASAP simvastatin arm.
In HeFH patients, a high plasma LDL-C is the single most
prominent risk factor for the development of cardiovascular
disease. Statins address this risk factor very efficiently in the
causal pathway of disease. Our data are in line with the
recently reported strong improvement in cardiovascular dis-
ease risk in HeFH patients.7 Although one might speculate
that the advent of high-dose statin and additional lipid-
lowering therapy may effectively have provided a “cure” for
HeFH, we emphasize that our results do not lend themselves
Table 3. Multivariate Analyses Into Baseline Determinants of
cIMT Change End Points
Parameter
Estimate (mm)
Standard
Error P Value
1-Year mean cIMT change
Prior statin use 0.01943 0.00794 0.015
Age 0.00055 0.00028 0.053
Baseline TG 0.00009 0.00004 0.054
Smoking 0.01465 0.00753 0.052
2-Year mean cIMT change
Prior statin use 0.01975 0.00982 0.045
Age 0.00077 0.00035 0.027
Baseline TG 0.00013 0.00006 0.022
Smoking 0.01999 0.00933 0.032
1-Year CCA-IMT change
Prior statin use 0.02819 0.00768 0.001
2-Year CCA-IMT change
Prior statin use 0.02059 0.00943 0.029
In these models, the variables prior statin use, age, sex, BMI 30 kg/m2,
history of CAD, history of diabetes, history of hypertension, and LDL-C, HDL-C,
and triglycerides (TG) at screening were entered into the models and only those
with a P0.10 were retained. Negative parameter estimates indicate a
negative association between the variable and the end point. Intercepts are not
shown.
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for such extrapolation. Although cIMT crudely reflects the
atherosclerotic process, the complications of atherosclerosis
also depend on other physical properties of the artery and the
degree of inflammation, which will also determine the like-
lihood of rupture and thrombosis.
cIMT Remains a Useful Surrogate End Point
It has consistently been shown, more than for any other
vascular imaging technique, that cIMT progression findings
parallel outcomes of clinical studies with similar interven-
tions.1 Although the results from the ENHANCE study9 have
led some to believe that a change in cIMT measurements may
not accurately reflect altered cardiovascular risk, the current
results consistently show that cIMT change remains sensitive
to changes in LDL-C levels. This reinvigorates the notion that
cIMT trials are very well equipped to provide an early
indication of the antiatherosclerotic efficacy of novel
compounds.
The response of carotid atherosclerosis progression to a
change in statin therapy also suggests that future cIMT trials
should ideally refrain from changing the statin regimen at the
start of the study, as to not influence subsequent cIMT
readings. A strong statin-induced cIMT decrease may obscure
the effects of the novel therapy assessed in that particular
study. In this respect, it is interesting to note that both
ENHANCE9 and RADIANCE 18 switched statin therapy at
the start of the study and found no difference in cIMT change
between their 2 treatment arms (simvastatin/ezetimibe versus
simvastatin alone, and torcetrapib/atorvastatatin versus ator-
vastatin alone, respectively), whereas CAPTIVATE10 did not
switch statins and did find a significant difference in cIMT
change between the 2 arms (pactimibe versus placebo).
Study Limitations
Some aspects of our analysis merit caution. Data on cIMT
were extracted from different studies that used different
ultrasound equipment and ultrasound protocols to obtain
cIMT measurements. Although we constructed a homoge-
neous measure of cIMT from the available data, it cannot be
excluded that these differences have negatively affected
between-trial comparability of cIMT readings at single time
points. However, the sole use of cIMT change values instead
of single cIMT measurements in this study can be expected to
mitigate such risk. In addition, our estimates of the determi-
nants of cIMT change in different analyses rely on the assump-
tion that variability is similarly explained across the individual
studies; these assumptions are consistent with—although
not proven by—similar analysis results in the individual
studies. Finally, this study carries all inherent limitations
of a post hoc analysis and its conclusions should be
considered hypothesis generating.
Conclusion
B-mode ultrasound cIMT has proven to be a sensitive marker
for the assessment of lipid altering pharmacotherapy. The rate
of cIMT change in contemporary HeFH patients has slowed
dramatically in relation to the use of intensive statin therapy
both before and during cIMT trials. This finding suggests
both a strong improvement in cardiovascular risk in HeFH
patients as well as a diminished suitability for inclusion in
cIMT trials that evaluate novel cardiovascular pharmacother-
apy. In the design of future cIMT studies, the occurrence of
rapid statin-induced vessel wall delipidation should be taken
into consideration.
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CLINICAL PERSPECTIVE
Patients with familial hypercholesterolemia, a hereditary disorder with severely elevated low-density lipoprotein
cholesterol levels, were once the individuals with the highest possible risk for an early heart attack. This was reflected by
the fact that the thickness of their carotid artery walls as well as their coronary angiograms showed the highest progression
over time when left untreated. This, however, was the situation before the introduction of statin therapy, and that has
dramatically changed the cause of disease and life for those unfortunate individuals. The results of the current study suggest
that with potent statin therapy, progression rates have come down to one third of what was previously reported. This is a
great improvement but by no means the solution for these patients. Familial hypercholesterolemia heterozygotes are often
far from low-density lipoprotein cholesterol goals and still require a lot of medical attention. We have also identified in
our study that patients with familial hypercholesterolemia who have been aggressively treated for many years and have
responded with regression of artery wall abnormalities are no longer ideal subjects for clinical studies into other
antiatherosclerotic modalities. These issues are relevant when designing clinical trials in this patient population.
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Table. Analyses into baseline determinants of 2 year mean cIMT change, by study 
  
Parameter estimate (mm) 
 
Standard error 
 
p-value 
 
ASAP 
    Prior statin use 
    Age     
    Baseline TG 
    Smoking 
 
 
0.02149 
0.00013   
-0.00019   
-0.00714 
 
 
0.02000 
0.00096 
0.00013 
0.02199  
 
 
0.283 
0.176 
0.161 
0.746 
RADIANCE 1 
    Prior statin use 
    Age     
    Baseline TG 
    Smoking 
 
0.01758 
0.00039 
-0.00006 
0.03465 
 
0.01840 
0.00049 
0.00009 
0.01518 
 
0.340 
0.426 
0.550 
0.023 
ENHANCE 
    Prior statin use 
    Age     
    Baseline TG 
    Smoking 
 
0.01862 
-0.00018 
0.00006 
0.00116 
  
0.00945 
0.00037 
0.00006 
0.00791 
 
0.049 
0.622 
0.287 
0.884 
CAPTIVATE 
    Prior statin use 
    Age     
    Baseline TG 
    Smoking 
 
 
0.00341 
0.00224 
-0.00034 
0.08330 
 
0.12710 
0.00135 
0.00016 
0.03231 
 
0.979 
0.010 
0.039 
0.011 
The direction of association between prior statin use and 2 year mean cIMT change is 
consistent across studies, if the statin regime is changed at the start of sthe study (i.e. in 
ASAP, RADIANCE 1 and ENHANCE). Negative parameter estimates indicate a negative 
association between the variable and the endpoint. Intercepts are not shown. 
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